Image of SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with
diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA

LITERATURE

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA


Chronic kidney disease (CKD) in patients with diabetes mellitus (DM) is a major problem of public health. currently, many of these patients experience progression of cardiovascular and renal disease, even when receiving optimal treatment. In previous years, several new drug classes for the treatment of type 2 DM
have emerged, including inhibitors of renal sodium–glucose cotransporter-2 (SGLT-2) and glucagon-like peptide-1 (GLP-1) receptor agonists


Availability

REQJ408-01Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
Nephrol Dial Transplant (2019) 34: 208–230
Statement of Responsibility

Other version/related

No other version available




Information


RECORD DETAIL


Back To Previous